AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Genmab launches HuMax-CD20 programme.(Genmab A/S developing antibodies to treat cancer)(Brief Article)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
Danish biotechnology company Genmab A/S has announced the start of its HuMax-CD20 programme, with the initial focus on the treatment of cancer.
The antibodies being developed under the programme target the CD20 antigen on B-cells, and Genmab will initially focus on developing the antibody for the treatment of Non-Hodgkin's Lymphoma, a cancer involving B-cells.
Antibodies targeting CD20 also have the potential to treat illnesses such as Crohn's disease, Wegener's Granulomatosis, …
-
- Genmab reports positive results from psoriasis drug trial.(Genmab A/S )(Brief...
-
Newspaper article from: M2 Europharma
April 15, 2002
700+ words
-
- Genmab and Roche expand antibody collaboration.(Brief Article)
-
Newspaper article from: M2 Europharma
June 10, 2002
700+ words
-
- Genmab to delist its share from Frankfurt.(Brief Article)
-
Newspaper article from: M2 Europharma
July 29, 2002
700+ words
-
- Genmab posts DKK247.6m operating loss for 2001.(Brief Article)
-
Newspaper article from: M2 Europharma
February 27, 2002
700+ words
-
- Genmab and Semaia team to develop cancer antibody therapeutic products....
-
Newspaper article from: M2 Europharma
August 1, 2002
700+ words
